<DOC>
	<DOCNO>NCT00758342</DOCNO>
	<brief_summary>To evaluate IOP ( Intraocular Pressure ) lower efficacy safety Brinzolamide 1.0 % ( Azopt ) , dosed twice daily adjunctive therapy patient treat Travoprost 0.004 % ( Travatan ) daily . The study double mask . The patient receive either treatment 12 week .</brief_summary>
	<brief_title>Azopt ( Brinzolamide 1.0 % ) Plus Travatan ( Travoprost 0.004 % ) Treating Patients With Chronic Angle-Closure Glaucoma ( CACG )</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>≥ 18 year ; CACG ( Chronic Angle Closure Glaucoma ) ≥ 1eye treat PGA ( prostaglandin analogue ) daily ≥ 2 week prior screen visit IOP=1932 mmHg ( millimeter mercury ) least one eye ≤ 32 mmHg eye clinical stability VA ( Visual Acuity ) optic nerve throughout study Abnormality restrict exam fundus anderior chamber conjunctivitis , keratitis uveitis unable discontinue use ocular hypotensive medication ( ) except Travatan ( Travoprost 0.004 % ) and/or Azopt ( Brinzolamide 1.0 % ) 12days4weeks ocular surgery prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>IOP lower efficacy safety Azopt plus Travatan</keyword>
</DOC>